Omega-3 Fatty Acid

Healio and Cardiology Today present highlights from the virtual American Heart Association Scientific Sessions, held Nov. 13 to 17.

Omega-3 fatty acids for reduction of CV events and death in older patients with prior MI.

Omega-3 carboxylic acid (Epanova, Novartis) vs. corn-oil placebo in statin-treated, high CV-risk adults with elevated triglycerides.

Healio and Cardiology Today have aggregated the most-read news from the virtual American Heart Association Scientific Sessions.

Healio and Cardiology Today have curated a list of the most-read cardiology news from November.

Four of the five top stories in cardiology last week were based on presentations from the virtual American Heart Association Scientific Sessions.

Omega-3 fatty acids yielded no reductions in subsequent CV events or death in older patients with prior MI, according to findings presented at the virtual American Heart Association Scientific Sessions.

Administration of high-dose omega-3 carboxylic acid compared with corn oil placebo did not reduce incidence of major adverse CV events among statin-treated adults with elevated triglycerides at high CV risk.

Taking omega-3 fatty acids and vitamin D3 supplements did not increase nor decrease the risk for incident atrial fibrillation over 5 years, according to results of the VITAL Rhythm trial.

Trials of novel medications and conversations on systemic racism and the ongoing COVID-19 pandemic are set to be featured at the virtual American Heart Association Scientific Sessions, which start Friday.